Compare Salesforce Inc (CRM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Mesoblast Limited — how do they compare? Salesforce Inc trades at $168.39 (market cap $137.23B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Salesforce Inc is far larger — about 64.7× Mesoblast Limited's market cap, and Salesforce Inc pays a 1.05% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| CRM | MESO | |
|---|---|---|
Market Cap | $137.23B | $2.12B |
Sector | Technology | Technology |
52-Week High | $270.25 | $20.96 |
52-Week Low | $150.12 | $10.96 |
Enterprise Value | $167.28B | $2.13B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% today, showing strong momentum despite recent sector volatility. The stock demonstrates robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected), impressive 77.64% gross margins, and accelerating revenue growth to $37.9B in 2025. Technical indicators show bullish momentum with the current price near pivot point resistance at $170, while analyst consensus remains strongly positive with a $235.90 price target.
The outlook remains favorable given Salesforce's dominant market position, AI-driven growth initiatives, and improving profitability. Key risks include sector-wide software selloffs, AI competition, and macroeconomic sensitivity. With 76.84% analyst buy ratings and strong institutional support, the stock appears undervalued relative to growth prospects despite near-term volatility concerns.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
